Results of a new study show some potential for a new drug-target in colorectal cancer, according to a report in the journal Oncology.
The authors said tumor progression is usually ensured by more than one proliferative mechanism. When a specifically targeted drug shuts one of these down, other mechanisms may emerge. Although these events may lead to treatment failure, they may also become an opportunity to identify novel targets that can be explored further, they said.
The study found that a combination of FOLFOX-4 and cetuximab is quite active and obtains long TTP with an acceptable toxicity profile. "Our results are in line with recent findings from phase II and phase III randomized studies providing strong evidence that the efficacy of anti-EGFR mAb is confined to patients with wild-type KRAS mCRC," researchers wrote.
Read the Oncology report on colorectal cancer.
Related articles on colorectal cancer.
Protein Biomarker Linked to Better Colorectal Cancer Survival for Obese
FDA Approves FUSILEV for Colorectal Cancer Patients
Missouri Surgeon Utilizes Novel Minimally Invasive Treatment for Colorectal Cancer